Yesterday Biogen announced the purchase of a single phase-2 ready neuro drug from Pfizer for $75 million upfront, plus milestones of up to $515 million and royalties.
The drug was being developed by Pzifer for the treatment of cognitive symptoms in schizophrenia, and has completed phase 1 safety trials.
The value of this deal is similar to Bell Potter’s estimate for trofinetide, however I think it is closer to what Neuren could get for NNZ-2591.
https://www.fiercebiotech.com/biote...unwanted-neuro-med-for-75m-as-sell-off-starts
- Forums
- ASX - By Stock
- pharmaceutical deals
Yesterday Biogen announced the purchase of a single phase-2...
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.03 |
Change
-0.695(3.35%) |
Mkt cap ! $2.570B |
Open | High | Low | Value | Volume |
$20.41 | $20.45 | $19.92 | $2.218M | 110.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 30 | $20.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.04 | 211 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 80 | 20.060 |
5 | 203 | 20.050 |
7 | 441 | 20.040 |
4 | 354 | 20.030 |
6 | 648 | 20.020 |
Price($) | Vol. | No. |
---|---|---|
20.070 | 1 | 1 |
20.080 | 50 | 1 |
20.090 | 75 | 1 |
20.100 | 263 | 3 |
20.110 | 697 | 4 |
Last trade - 12.31pm 25/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online